Literature DB >> 268650

In vitro and in vivo correlation of clotting protease activity: effect of heparin.

S N Gitel, R C Stephenson, S Wessler.   

Abstract

The thrombogenicity of three highly purified proteases (thrombin, activated Factor X, and activated Factor IX) was determined quantitatively in an animal model. The minimal amounts required to produce a standard score 4 thrombus were 1.1 nmol for thrombin, 0.12 nmol for activated Factor X, and 0.018 nmol for activated Factor IX. After the administration of heparin at 5, 10, and 20 units/kg in rabbits, the thrombogenicity of each of these proteases decreased progressively. The heparin-induced inhibition of thrombosis decreased in the order, activated Factor IX > activated Factor X > thrombin at each heparin concentration. These differences were statistically significant. These in vivo data provide support for the following hypotheses originally developed from in vitro experiments: (i) activation of the blood coagulation system, which proceeds through a cascade mechanism, incorporates biochemical amplification; (ii) the inhibition of activated Factor IX by antithrombin III in the presence of heparin is an important reaction in the prevention of thrombosis; (iii) less heparin is required to inhibit thrombosis prior to thrombin generation than afterward; (iv) an increase in the reactivity of antithrombin III reflects a decreased tendency to thrombosis while a decrease in this reactivity reflects an increased tendency to thrombosis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 268650      PMCID: PMC431395          DOI: 10.1073/pnas.74.7.3028

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  35 in total

1.  AN ENZYME CASCADE IN THE BLOOD CLOTTING MECHANISM, AND ITS FUNCTION AS A BIOCHEMICAL AMPLIFIER.

Authors:  R G MACFARLANE
Journal:  Nature       Date:  1964-05-02       Impact factor: 49.962

2.  WATERFALL SEQUENCE FOR INTRINSIC BLOOD CLOTTING.

Authors:  E W DAVIE; O D RATNOFF
Journal:  Science       Date:  1964-09-18       Impact factor: 47.728

3.  INHERITED ANTITHROMBIN DEFICIENCY CAUSING THROMBOPHILIA.

Authors:  O EGEBERG
Journal:  Thromb Diath Haemorrh       Date:  1965-06-15

4.  Thrombosis in the presence of vascular stasis.

Authors:  S WESSLER
Journal:  Am J Med       Date:  1962-11       Impact factor: 4.965

5.  Biologic assay of a thrombosis-inducing activity in human serum.

Authors:  S WESSLER; S M REIMER; M C SHEPS
Journal:  J Appl Physiol       Date:  1959-11       Impact factor: 3.531

6.  Effects of vitamin B12, B6 and procaine on the conditioned escape response.

Authors:  R KIESEWETTER; R ITTERHEIM; J GEBHARD
Journal:  Nature       Date:  1962-03-24       Impact factor: 49.962

7.  Studies on the antithrombin and heparin cofactor activities of a fraction adsorbed from plasma by aluminum hydroxide.

Authors:  F C MONKHOUSE; E S FRANCE; W H SEEGERS
Journal:  Circ Res       Date:  1955-07       Impact factor: 17.367

8.  Quantitative aspects of antithrombin and heparin in plasma.

Authors:  D F WAUGH; M A FITZGERALD
Journal:  Am J Physiol       Date:  1956-03

9.  Anticoagulant therapy in surgery.

Authors:  G DE TAKATS
Journal:  J Am Med Assoc       Date:  1950-02-25

10.  Estrogen-containing oral contraceptive agents. A basis for their thrombogenicity.

Authors:  S Wessler; S N Gitel; L S Wan; B S Pasternack
Journal:  JAMA       Date:  1976-11-08       Impact factor: 56.272

View more
  7 in total

Review 1.  Mechanism of the anticoagulant action of heparin.

Authors:  I Björk; U Lindahl
Journal:  Mol Cell Biochem       Date:  1982-10-29       Impact factor: 3.396

2.  Elevated Plasma Factor IXa Activity in Premenopausal Women on Hormonal Contraception.

Authors:  Pansakorn Tanratana; Paul Ellery; Pamela Westmark; Alan E Mast; John P Sheehan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-11-02       Impact factor: 8.311

Review 3.  Occlusive vascular diseases in oral contraceptive users. Epidemiology, pathology and mechanisms.

Authors:  I F Godsland; U Winkler; O Lidegaard; D Crook
Journal:  Drugs       Date:  2000-10       Impact factor: 9.546

Review 4.  Factor IX(a) inhibitors: an updated patent review (2003-present).

Authors:  Daniel K Afosah; Edward Ofori; Madhusoodanan Mottamal; Rami A Al-Horani
Journal:  Expert Opin Ther Pat       Date:  2022-01-17       Impact factor: 6.674

5.  Low molecular weight heparin inhibits plasma thrombin generation via direct targeting of factor IXa: contribution of the serpin-independent mechanism.

Authors:  Y Buyue; T M Misenheimer; J P Sheehan
Journal:  J Thromb Haemost       Date:  2012-10       Impact factor: 5.824

6.  Active site-blocked factor IXa prevents intravascular thrombus formation in the coronary vasculature without inhibiting extravascular coagulation in a canine thrombosis model.

Authors:  C R Benedict; J Ryan; B Wolitzky; R Ramos; M Gerlach; P Tijburg; D Stern
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

Review 7.  Translation and Clinical Development of Antithrombotic Aptamers.

Authors:  Shahid M Nimjee; Thomas J Povsic; Bruce A Sullenger; Richard C Becker
Journal:  Nucleic Acid Ther       Date:  2016-02-16       Impact factor: 5.486

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.